Post-Hoc Live: Did the US just kill off China biotech deals?

The Treasury Department’s proposed rule would implement the COINS Act, a 2025 law governing US investment in sensitive technologies in China and other countries. Its most surprising feature for biotech is the inclusion of a broad set of drug technologies among prohibited investments. This matters because China-related transactions have become central to biopharma dealmaking.

The article does not provide a complete list of covered technologies or explain every investment restriction. It does establish the key mechanism: the rule would prohibit certain investments, rather than merely asking companies to report them or seek approval. The affected transactions could therefore include some deals involving Chinese drug technology companies, although the exact boundaries remain unclear.

The proposed rule has not automatically ended all China biotech activity. The industry is still assessing what the language means, and the article frames the outcome as an open question. Companies, investors, and policymakers will need to determine the final scope and whether the rule actually reduces or reshapes China-related deals.

The COINS Act is the 2025 law that governs US investment in sensitive technologies in China and other countries. The article presents it as the legal foundation for Treasury’s proposed rule. Its importance comes from bringing investment activity, not only trade or research, into a framework focused on sensitive technology.

The proposed rule supplies the operating details described in the article. Most notably, it places a broad set of drug technologies on the list of prohibited investments. The article does not describe every category, transaction type, exception, or enforcement process, so the full regulatory mechanism cannot be determined from the provided text.

For biotech, the immediate issue is uncertainty over scope and effect. The law exists, but Treasury’s proposal is still being examined by the industry. The next practical question is whether the final rule preserves, limits, or eliminates particular US-China investment structures. The article does not say when that decision will occur.

The proposed rule covers a broad set of drug technologies, according to the article. That breadth is the central surprise. It suggests the policy may reach well beyond a small number of narrowly defined transactions, making the rule potentially important across biopharma investing and dealmaking.

The article gives no number of technologies, named categories, company examples, or complete definition. It only states that a broad set of drug technologies made the list of prohibited investments. Therefore, the available evidence supports a description of wide coverage, but not a precise estimate of how many products, platforms, or companies could be affected.

The industry is still working out what the language means. The proposed rule could affect China-related deals differently depending on the technology and transaction involved, but the article does not provide those distinctions. Its main implication is uncertainty: companies must assess the final rule before knowing whether particular investments remain possible.

China-related dealmaking has been the backbone of biopharma mergers and acquisitions over the past two years. The article also says these transactions created dozens of new companies and partnerships. That makes China more than a side market: it has been a major source of corporate formation and collaboration across biopharma.

The article does not provide a dollar value, deal count, or breakdown between acquisitions, mergers, licensing arrangements, and partnerships. Its concrete scale markers are qualitative: China deals are described as the backbone of M&A, and they have produced dozens of new companies and partnerships. Those facts show substantial activity without measuring its exact financial size.

That established role explains why the proposed investment prohibitions have drawn immediate attention. Restricting some investments could affect a large part of the industry’s recent dealmaking model. The likely impact depends on which drug technologies and transactions the final rule covers, an issue the article says remains under discussion.

Prohibiting investments in covered drug technologies could disrupt a dealmaking channel that has supported biopharma M&A for the past two years. It could make some acquisitions, mergers, or company-creation partnerships impossible for US investors. The stakes are high because China transactions have been described as the sector’s backbone.

The key mechanism is direct: if a proposed transaction is an investment prohibited by the rule, the US side could not pursue it in its current form. The article does not identify specific deals, companies, or structures that would be blocked. It also does not say whether every China-related transaction would fall inside the rule.

The near-term reality is uncertainty rather than a confirmed shutdown. The article asks whether the rule will kill off China deals and reports that the industry is reacting to the fast-moving proposal. Future effects will depend on the final language, the technologies covered, and how companies adapt their transactions.

The article does not discuss alternatives for companies facing restricted direct investment. In general, biotech companies could explore licensing drug rights, research collaborations, joint ventures, or funding from investors outside the restricted system. These routes could preserve cooperation without using the exact investment structure prohibited by the rule.

Licensing is different from buying an ownership stake, while a partnership can be designed around research, development, or commercial rights. Other possible routes include domestic financing, public funding, or strategic investment from parties not covered by the restrictions. Whether any option is available would depend on the final rule’s definitions and the specific technology involved.

These are established business alternatives, not solutions confirmed by the article. The proposed rule is still being assessed, and the text does not say which arrangements would remain legal. Companies may therefore need to redesign deals, delay them, or abandon them if no compliant structure supports the same scientific and commercial goals.

The article does not explain why biotechnology is classified as sensitive technology. More broadly, drug and biotechnology capabilities can matter for public health, biological security, national security, and strategic competition. Those concerns can lead governments to scrutinize not only products, but also the knowledge, platforms, data, and companies behind them.

Investment deals help move discoveries toward medicines by supplying capital and connecting researchers with development, manufacturing, regulatory, and commercial expertise. They can also create new companies and partnerships. The article directly supports this last point: China dealmaking has created dozens of new companies and partnerships and has been central to biopharma M&A.

That connection explains the policy conflict. Supporters of open dealmaking emphasize the flow of drugs, ideas, and deals. Opponents argue that some transactions should be stopped. The proposed rule brings that disagreement into practice by placing a broad set of drug technologies among prohibited investments, although its final effect remains uncertain.